BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8390975)

  • 1. The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis.
    Takada H; Kishimoto C; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
    Heart Vessels; 1993; 8(2):59-66. PubMed ID: 8390975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells.
    Kishimoto C; Takada H; Kuroki Y; Matsushita I; Hiraoka Y; Kurokawa M; Ochiai H; Sasayama S
    Cardiovasc Res; 1993 Feb; 27(2):243-8. PubMed ID: 8386064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of effects of cyclosporine on myocardial lymphocyte subsets in Coxsackievirus B3 myocarditis in the aviremic stage.
    Kishimoto C; Abelmann WH
    Circ Res; 1989 Oct; 65(4):934-45. PubMed ID: 2551533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.
    Kishimoto C; Kuroki Y; Hiraoka Y; Ochiai H; Kurokawa M; Sasayama S
    Circulation; 1994 Jun; 89(6):2836-42. PubMed ID: 8205699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of granulocyte colony-stimulating factor upon coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Takada H; Suzaki N; Shiraki K
    Eur Heart J; 1995 Dec; 16(12):1900-6. PubMed ID: 8682024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis.
    Kishimoto C; Thorp KA; Abelmann WH
    Circulation; 1990 Sep; 82(3):982-9. PubMed ID: 2168299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial immunologic identification of lymphocyte subsets in murine coxsackievirus B3 myocarditis: different kinetics and significance of lymphocyte subsets in the heart and in peripheral blood.
    Kishimoto C; Misaki T; Crumpacker CS; Abelmann WH
    Circulation; 1988 Mar; 77(3):645-53. PubMed ID: 2830046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model. Antiviral and anti-inflammatory effects.
    Takada H; Kishimoto C; Hiraoka Y
    Circulation; 1995 Sep; 92(6):1604-11. PubMed ID: 7664447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated immune enhancement in coxsackievirus B3 myocarditis.
    Kishimoto C; Kurokawa M; Ochiai H
    J Mol Cell Cardiol; 2002 Sep; 34(9):1227-38. PubMed ID: 12392896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo significance of T cells in the development of Coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury.
    Kishimoto C; Abelmann WH
    Circ Res; 1990 Sep; 67(3):589-98. PubMed ID: 1697791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model.
    Cabinian AE; Kiel RJ; Smith F; Ho KL; Khatib R; Reyes MP
    J Lab Clin Med; 1990 Apr; 115(4):454-62. PubMed ID: 2157783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine activated killer cells in murine coxsackievirus B3 myocarditis.
    Kishimoto C; Kuroki Y; Kurokawa M; Ohiai H
    Basic Res Cardiol; 1997 Dec; 92(6):402-9. PubMed ID: 9464864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice.
    Kishimoto C; Abelmann WH
    Circulation; 1989 Jun; 79(6):1300-8. PubMed ID: 2541943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    Cardiovasc Res; 1992 Oct; 26(10):956-61. PubMed ID: 1336713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets.
    Kishimoto C; Crumpacker CS; Abelmann WH
    J Am Coll Cardiol; 1988 Nov; 12(5):1334-41. PubMed ID: 2844874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lobenzarit on murine acute viral myocarditis.
    Yokoyama T; Kanda T; Suzuki T; Murata K
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):403-7. PubMed ID: 1325832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence.
    Kiel RJ; Smith FE; Chason J; Khatib R; Reyes MP
    Eur J Epidemiol; 1989 Sep; 5(3):348-50. PubMed ID: 2551723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of pre-existing coxsackievirus B4 myocardial disease on the expression of coxsackievirus B3 myocarditis.
    Khatib R; Reyes MP; Khatib G; Giraldo A
    Can J Cardiol; 1993 Jun; 9(5):444-7. PubMed ID: 8394194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of oxygen derived free radicals in the pathogenesis of coxsackievirus B3 myocarditis in mice.
    Hiraoka Y; Kishimoto C; Takada H; Kurokawa M; Ochiai H; Shiraki K; Sasayama S
    Cardiovasc Res; 1993 Jun; 27(6):957-61. PubMed ID: 8221785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.